



Clinical trial results:

Tralokinumab in combination with topical corticosteroids for moderate-to-severe atopic dermatitis - ECZTRA 3. A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

Summary

EudraCT number	2017-002065-21
Trial protocol	GB NL ES BE DE
Global end of trial date	26 September 2019

Results information

Result version number	v1
This version publication date	10 October 2020
First version publication date	10 October 2020

Trial information

Trial identification

Sponsor protocol code	LP0162-1339
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03363854
WHO universal trial number (UTN)	-
Other trial identifiers	ClinicalTrials.gov : NCT03363854

Notes:

Sponsors

Sponsor organisation name	LEO Pharma A/S
Sponsor organisation address	Industriparken 55, Ballerup, Denmark, 2750
Public contact	Clinical Disclosure Specialist, LEO Pharma A/S, +45 44945888, disclosure@leo-pharma.com
Scientific contact	Clinical Disclosure Specialist, LEO Pharma A/S, +45 44945888, disclosure@leo-pharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 September 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 September 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis.

Protection of trial subjects:

This clinical trial was conducted to conform to the principles of the Declaration of Helsinki as adopted by the 18th World Medical Association General Assembly (1964) and subsequent amendments.

All subjects received written and verbal information concerning the clinical trial.

Subjects were asked to consent that their personal data were recorded, collected, processed and could be transferred to EU and non-EU countries in accordance with any national legislation regulating privacy and data protection.

In the treatment period, which consisted of an initial treatment period and a continuation treatment period, some subjects were treated with placebo. If medically necessary (i.e. to control intolerable atopic dermatitis [AD] symptoms), rescue treatment for AD could be provided to subjects at the discretion of the investigator.

During the first 3 dosing visits in both the initial treatment period (i.e. at Weeks 0, 2, and 4) and the continuation treatment period (i.e. at Weeks 16, 18, and 20), subjects were monitored after administration of the investigational medicinal product for immediate drug reactions for a minimum of 30 min with vital signs taken at 30 min or until stable, whichever was later.

Appropriate drugs, such as epinephrine, anti-histamines, corticosteroids, etc., and medical equipment to treat acute anaphylactic reactions were immediately available at the trial sites and trial personnel was trained to recognise and respond to anaphylaxis according to local guidelines.

Background therapy:

All subjects were required to use an emollient twice daily (or more as needed) for at least 14 days before randomisation and to continue this treatment throughout the trial until the end of the safety follow-up period.

Evidence for comparator: -

Actual start date of recruitment	08 February 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 16
Country: Number of subjects enrolled	Poland: 67
Country: Number of subjects enrolled	Spain: 27
Country: Number of subjects enrolled	United Kingdom: 34
Country: Number of subjects enrolled	Belgium: 19
Country: Number of subjects enrolled	Germany: 57
Country: Number of subjects enrolled	United States: 100
Country: Number of subjects enrolled	Canada: 60

Worldwide total number of subjects	380
EEA total number of subjects	220

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	356
From 65 to 84 years	24
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

After the subject gave informed consent, they went through a 2- to 6-week screening period for washout of previous atopic dermatitis medication and disallowed medication. The subject was randomised to treatment at Week 0.

Period 1

Period 1 title	Initial treatment period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

Subjects were randomised to initial treatment at Week 0. This was a double-blinded trial where tralokinumab and placebo were visually distinct from each other and not matched for viscosity. They were therefore handled and administered by a qualified unblinded health care professional at the site who was not involved in the management of trial subjects and who did not perform any of the assessments.

Arms

Are arms mutually exclusive?	Yes
Arm title	Tralokinumab Q2W+TCS

Arm description:

Subjects in the initial treatment period (Week 0 to Week 16) treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed.

Arm type	Experimental
Investigational medicinal product name	Tralokinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received a loading dose of 600 mg tralokinumab at Week 0 followed by a dose of 300 mg tralokinumab Q2W from Week 2 to Week 16. The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Arm title	Placebo+TCS
------------------	-------------

Arm description:

Subjects in the initial treatment period (Week 0 to Week 16) treated with placebo every second week and topical corticosteroid (TCS) as needed.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were administered placebo at Week 0 followed by administration of placebo every second week from Week 2 to Week 16. The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Number of subjects in period 1	Tralokinumab Q2W+TCS	Placebo+TCS
Started	253	127
Completed	235	120
Not completed	18	7
Consent withdrawn by subject	6	1
Subject not dosed	1	1
Adverse event, non-fatal	5	1
Other	1	3
Lost to follow-up	4	-
Lack of efficacy	1	1

Period 2

Period 2 title	Continuation treatment period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

Subjects who achieved Investigator's Global Assessment score of 0 or 1 at Week 16 or a reduction in Eczema Area and Severity Index of at least 75% at Week 16 were re-randomised to continuation treatment at Week 16. The other subjects were assigned treatment in a blinded manner.

Arms

Are arms mutually exclusive?	Yes
Arm title	Tralokinumab R/Q2W+TCS

Arm description:

Subjects treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as Investigator's Global Assessment score of 0 or 1 at Week 16 or a reduction in Eczema Area and Severity Index of at least 75% at Week 16 achieved without rescue medication, and re-randomised to tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32).

Arm type	Experimental
Investigational medicinal product name	Tralokinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received a dose of 300 mg tralokinumab Q2W from Week 16 to Week 30. The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Arm title	Tralokinumab R/Q4W+TCS
-----------	------------------------

Arm description:

Subjects treated with tralokinumab every second week and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as Investigator's Global Assessment score of 0 or 1 at Week 16 or a reduction in Eczema Area and Severity Index of at least 75% at Week 16 achieved without rescue medication, and re-randomised to tralokinumab every fourth week (Q4W) and TCS as needed in the continuation treatment period (Week 16 to Week 32).

Arm type	Experimental
Investigational medicinal product name	Tralokinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received alternating doses of 300 mg tralokinumab and placebo every second week from Week 16 to Week 30. The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Arm title	Tralokinumab NR/Q2W+TCS
------------------	-------------------------

Arm description:

Subjects treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), without a clinical response at Week 16 (NR: non-responder) i.e. not having Investigator's Global Assessment score of 0 or 1 at Week 16 nor a reduction in Eczema Area and Severity Index of at least 75% at Week 16, and assigned tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32).

Arm type	Experimental
Investigational medicinal product name	Tralokinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received a dose of 300 mg tralokinumab Q2W from Week 16 to Week 30. The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Arm title	Placebo NR/tralokinumab Q2W+TCS
------------------	---------------------------------

Arm description:

Subjects treated with placebo every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), without a clinical response at Week 16 (NR: non-responder) i.e. not having Investigator's Global Assessment score of 0 or 1 at Week 16 nor a reduction in Eczema Area and Severity Index of at least 75% at Week 16, and assigned tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32).

Arm type	Experimental
Investigational medicinal product name	Tralokinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received a dose of 300 mg tralokinumab Q2W from Week 16 to Week 30. The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Arm title	Placebo R/placebo+TCS
------------------	-----------------------

Arm description:

Subjects treated with placebo every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as Investigator's Global Assessment score of 0 or 1 at Week 16 or a reduction in Eczema Area and Severity Index of at least 75% at Week 16 achieved without rescue medication, and assigned placebo Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32).

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects were administered placebo Q2W from Week 16 to Week 30. The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Number of subjects in period 2^[1]	Tralokinumab R/Q2W+TCS	Tralokinumab R/Q4W+TCS	Tralokinumab NR/Q2W+TCS
Started	69	69	95
Completed	68	65	87
Not completed	1	4	8
Consent withdrawn by subject	-	1	1
Adverse event, non-fatal	-	1	-
Other	1	2	2
Lost to follow-up	-	-	2
Lack of efficacy	-	-	3

Number of subjects in period 2^[1]	Placebo NR/tralokinumab Q2W+TCS	Placebo R/placebo+TCS
Started	79	41
Completed	72	38
Not completed	7	3
Consent withdrawn by subject	2	1
Adverse event, non-fatal	2	1
Other	2	1
Lost to follow-up	-	-
Lack of efficacy	1	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Between the initial and continuation treatment periods, 2 subjects permanently discontinued treatment.

Period 3

Period 3 title	Safety follow-up period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

No treatment was administered to the subjects during the safety follow-up period and therefore no randomisation took place. However, double blinding was maintained throughout the period.

Arms

Arm title	Subjects in the safety follow-up period
Arm description: Subjects who spent any amount of time in the safety follow-up period, independently of the treatment(s) received before. No treatment was administered to the subjects during this period. In selected countries, eligible subjects who completed treatment could transfer to an open-label long-term extension trial (conducted under a separate protocol) at any any time during the safety follow-up period.	
Arm type	No treatment
No investigational medicinal product assigned in this arm	

Number of subjects in period 3 ^[2]	Subjects in the safety follow-up period
Started	278
Completed	62
Not completed	216
Consent withdrawn by subject	16
Transferred to extension trial	180
Other	8
Lost to follow-up	12

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Subjects could start the safety follow-up (SFU) period at any time during the trial, not only after the continuation treatment period. Among the 330 subjects who completed continuation treatment, 242 entered SFU, 84 transferred to a long extension trial without entering SFU, and 4 withdrew from the trial without entering SFU. 278 subjects entered SFU, 36 after withdrawal in the initial period, 16 after withdrawal in the continuation period, and 242 after continuation treatment.

Period 4

Period 4 title	Entire trial period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

The entire trial consisted of an initial and a continuation treatment period followed by a safety follow-up period (SFU). Subjects were randomised to initial treatment at Week 0. Subjects who achieved Investigator's Global Assessment score of 0 or 1 at Week 16 or a reduction in Eczema Area and Severity Index of at least 75% at Week 16 were re-randomised to continuation treatment at Week 16. The other subjects were assigned treatment in a blinded manner. Subjects were not treated in the SFU.

Arms

Are arms mutually exclusive?	No
------------------------------	----

Arm title	Tralokinumab+TCS
Arm description: Subjects treated with tralokinumab (independently of regimen) and topical corticosteroid (TCS) prior to antidrug antibody (ADA) assessment. Group defined for reporting ADA data over the entire trial, i.e. including the off-treatment safety follow-up period.	
Arm type	Experimental
Investigational medicinal product name	Tralokinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Arm title	Tralokinumab naive
Arm description: Subjects not exposed to tralokinumab (i.e. treated with placebo and topical corticosteroid) prior to antidrug antibody (ADA) assessment. Group defined for reporting ADA data over the entire trial, i.e. including the off-treatment safety follow-up period.	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

The injections were administered in the subcutaneous tissue of the upper arm, anterior thigh, or abdomen.

Number of subjects in period 4	Tralokinumab+TCS	Tralokinumab naive
Started	331	126
Completed	331	126

Baseline characteristics

Reporting groups

Reporting group title	Tralokinumab Q2W+TCS
-----------------------	----------------------

Reporting group description:

Subjects in the initial treatment period (Week 0 to Week 16) treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed.

Reporting group title	Placebo+TCS
-----------------------	-------------

Reporting group description:

Subjects in the initial treatment period (Week 0 to Week 16) treated with placebo every second week and topical corticosteroid (TCS) as needed.

Reporting group values	Tralokinumab Q2W+TCS	Placebo+TCS	Total
Number of subjects	253	127	380
Age categorical			
Units: Subjects			
Adults (18-64 years)	237	119	356
From 65-84 years	16	8	24
Age continuous			
Units: years			
arithmetic mean	39.8	37.7	
standard deviation	± 15.3	± 14.8	-
Gender categorical			
Units: Subjects			
Female	128	43	171
Male	125	84	209

End points

End points reporting groups

Reporting group title	Tralokinumab Q2W+TCS
Reporting group description: Subjects in the initial treatment period (Week 0 to Week 16) treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed.	
Reporting group title	Placebo+TCS
Reporting group description: Subjects in the initial treatment period (Week 0 to Week 16) treated with placebo every second week and topical corticosteroid (TCS) as needed.	
Reporting group title	Tralokinumab R/Q2W+TCS
Reporting group description: Subjects treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as Investigator's Global Assessment score of 0 or 1 at Week 16 or a reduction in Eczema Area and Severity Index of at least 75% at Week 16 achieved without rescue medication, and re-randomised to tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32).	
Reporting group title	Tralokinumab R/Q4W+TCS
Reporting group description: Subjects treated with tralokinumab every second week and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as Investigator's Global Assessment score of 0 or 1 at Week 16 or a reduction in Eczema Area and Severity Index of at least 75% at Week 16 achieved without rescue medication, and re-randomised to tralokinumab every fourth week (Q4W) and TCS as needed in the continuation treatment period (Week 16 to Week 32).	
Reporting group title	Tralokinumab NR/Q2W+TCS
Reporting group description: Subjects treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), without a clinical response at Week 16 (NR: non-responder) i.e. not having Investigator's Global Assessment score of 0 or 1 at Week 16 nor a reduction in Eczema Area and Severity Index of at least 75% at Week 16, and assigned tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32).	
Reporting group title	Placebo NR/tralokinumab Q2W+TCS
Reporting group description: Subjects treated with placebo every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), without a clinical response at Week 16 (NR: non-responder) i.e. not having Investigator's Global Assessment score of 0 or 1 at Week 16 nor a reduction in Eczema Area and Severity Index of at least 75% at Week 16, and assigned tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32).	
Reporting group title	Placebo R/placebo+TCS
Reporting group description: Subjects treated with placebo every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as Investigator's Global Assessment score of 0 or 1 at Week 16 or a reduction in Eczema Area and Severity Index of at least 75% at Week 16 achieved without rescue medication, and assigned placebo Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32).	
Reporting group title	Subjects in the safety follow-up period
Reporting group description: Subjects who spent any amount of time in the safety follow-up period, independently of the treatment(s) received before. No treatment was administered to the subjects during this period. In selected countries, eligible subjects who completed treatment could transfer to an open-label long-term extension trial (conducted under a separate protocol) at any any time during the safety follow-up period.	
Reporting group title	Tralokinumab+TCS
Reporting group description: Subjects treated with tralokinumab (independently of regimen) and topical corticosteroid (TCS) prior to antidrug antibody (ADA) assessment. Group defined for reporting ADA data over the entire trial, i.e.	

including the off-treatment safety follow-up period.

Reporting group title	Tralokinumab naive
Reporting group description: Subjects not exposed to tralokinumab (i.e. treated with placebo and topical corticosteroid) prior to antidrug antibody (ADA) assessment. Group defined for reporting ADA data over the entire trial, i.e. including the off-treatment safety follow-up period.	

Primary: Subjects with Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Week 16

End point title	Subjects with Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Week 16
-----------------	--

End point description:

IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe). Results of the primary analysis of the primary estimand are reported below. The other analyses supported these results. The analysis was based on the full analysis set (FAS). Of the 380 subjects randomised to initial treatment, 378 were treated. Therefore, the FAS consisted of 378 subjects.

End point type	Primary
----------------	---------

End point timeframe:

At Week 16

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: Number of subjects	98	33		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
-----------------------------------	-------------------------------------

Statistical analysis description:

Subjects who achieved IGA 0 or 1 at Week 16 were defined as responders. Subjects with missing data at Week 16 or who received rescue medication prior to Week 16 were defined as non-responders, independently of their IGA value at Week 16. The null hypothesis of no difference in response rates between tralokinumab Q2W+TCS and placebo+TCS was tested against the 2-sided alternative that there was a difference. Results reported are based on primary analysis of primary estimand.

Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.015 ^[1]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	12.4

Confidence interval	
level	95 %
sides	2-sided
lower limit	2.9
upper limit	21.9

Notes:

[1] - The primary endpoints were tested sequentially at a 5% significance level. The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.

Primary: Subjects achieving at least 75% reduction in Eczema Area and Severity Index (EASI) at Week 16

End point title	Subjects achieving at least 75% reduction in Eczema Area and Severity Index (EASI) at Week 16
-----------------	---

End point description:

EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition. Results of the primary analysis of the primary estimand are reported below. The other analyses supported these results. The analysis was based on the full analysis set (FAS). Of the 380 subjects randomised to initial treatment, 378 were treated. Therefore, the FAS consisted of 378 subjects.

End point type	Primary
----------------	---------

End point timeframe:

At Week 16

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: Number of subjects	141	45		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS
----------------------------	----------------------

Statistical analysis description:

Subjects who achieved at least 75% reduction in EASI at Week 16 were defined as responders. Subjects with missing data at Week 16 or who received rescue medication prior to Week 16 were defined as non-responders, independently of their EASI value at Week 16. The null hypothesis of no difference in response rates between tralokinumab Q2W+TCS and placebo+TCS was tested against the 2-sided alternative that there was a difference. Results reported are based on primary analysis of primary estimand.

Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[2]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	20.2

Confidence interval	
level	95 %
sides	2-sided
lower limit	9.8
upper limit	30.6

Notes:

[2] - The primary endpoints were tested sequentially at a 5% significance level. The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.

Secondary: Reduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (weekly average) of at least 4 from baseline to Week 16

End point title	Reduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (weekly average) of at least 4 from baseline to Week 16
-----------------	--

End point description:

Worst Daily Pruritus NRS is used by the subject to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale. Results of the primary analysis of the primary estimand are reported below. The other analyses supported these results. The analysis was based on subjects in the full analysis set with a Worst Daily Pruritus NRS (weekly average) of at least 4 at baseline (Week 0).

End point type	Secondary
----------------	-----------

End point timeframe:

Week 0 to Week 16

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	249	126		
Units: Number of subjects	113	43		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
----------------------------	-------------------------------------

Statistical analysis description:

Subjects meeting the endpoint were defined as responders. Subjects with missing data at Week 16 or who received rescue medication prior to Week 16 were defined as non-responders, independently of their Worst daily Pruritus NRS value at Week 16. Results reported are based on primary analysis of primary estimand.

Comparison groups	Placebo+TCS v Tralokinumab Q2W+TCS
Number of subjects included in analysis	375
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.037 ^[3]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	11.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	21.6

Notes:

[3] - This secondary endpoint was tested sequentially using the Holm method for multiplicity adjustment at a 5% significance level after the sequential testing of the primary endpoints, if these showed statistical significance.

Secondary: Change in Scoring Atopic Dermatitis (SCORAD) from baseline to Week 16

End point title	Change in Scoring Atopic Dermatitis (SCORAD) from baseline to Week 16
End point description: SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition. Results of the primary analysis of the primary estimand are reported below. The other analyses supported these results. The analysis was based on the full analysis set.	
End point type	Secondary
End point timeframe: Week 0 to Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: units on a scale				
arithmetic mean (standard error)	-37.7 (± 1.25)	-26.8 (± 1.80)		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description: Data collected after permanent discontinuation of investigational medicinal product or initiation of rescue medication were not included. Results reported are based on primary analysis of primary estimand.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[4]
Method	Repeated measurements model
Parameter estimate	Difference
Point estimate	-10.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-15.2
upper limit	-6.6

Notes:

[4] - This secondary endpoint was tested sequentially using the Holm method for multiplicity adjustment at a 5% significance level after the sequential testing of the primary endpoints, if these showed statistical significance.

Secondary: Change in Dermatology Life Quality Index (DLQI) score from baseline to

Week 16

End point title	Change in Dermatology Life Quality Index (DLQI) score from baseline to Week 16
-----------------	--

End point description:

DLQI is used by the subject to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL. Results of the primary analysis of the primary estimand are reported below. The other analyses supported these results. The analysis was based on the full analysis set.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 0 to Week 16

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: units on a scale				
arithmetic mean (standard error)	-11.7 (± 0.39)	-8.8 (± 0.56)		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
----------------------------	-------------------------------------

Statistical analysis description:

Data collected after permanent discontinuation of investigational medicinal product or initiation of rescue medication were not included. Results reported are based on primary analysis of primary estimand.

Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[5]
Method	Repeated measurements model
Parameter estimate	Difference
Point estimate	-2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.3
upper limit	-1.6

Notes:

[5] - This secondary endpoint was tested sequentially using the Holm method for multiplicity adjustment at a 5% significance level after sequential testing of the primary endpoints, if these showed statistical significance.

Secondary: Frequency of anti-drug antibodies (ADA)

End point title	Frequency of anti-drug antibodies (ADA)
-----------------	---

End point description:

Presence of ADA from Week 0 to Week 46 was measured. Data were reported in the following categories: positive (presence of ADA at baseline and/or presence of ADA at at least 1 post-baseline

assessment), perishing (presence of ADA at baseline and absence of ADA at all post-baseline assessments), negative (absence of ADA at all assessments). The analysis was based on the safety analysis set, defined as identical to the full analysis set and therefore consisting of 378 subjects in total. Due to the definition of the analysis groups, subjects could contribute to 1 or the 2 groups which is why the sum of subjects from the 2 groups does not equal 378.

End point type	Secondary
End point timeframe:	
Week 0 to Week 46	

End point values	Tralokinumab+ TCS	Tralokinumab naive		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	126		
Units: Number of subjects				
Positive	8	4		
Perishing	2	0		
Negative	316	122		
No post-baseline ADA assessment	5	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Amount of topical corticosteroid (TCS) used through Week 16 assuming no TCS used from the non-returned tubes

End point title	Amount of topical corticosteroid (TCS) used through Week 16 assuming no TCS used from the non-returned tubes
-----------------	--

End point description:

Assessed as the amount of TCS weighed from previous visits, assuming no TCS was used from the non-returned tubes. The analysis was based on the full analysis set. The results of Week 15 to Week 16 are reported below.

End point type	Secondary
End point timeframe:	
Week 0 to Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: gram(s)				
arithmetic mean (standard error)	11.6 (± 1.57)	20.2 (± 2.27)		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description: Data collected after permanent discontinuation of investigational medicinal product or initiation of rescue medication were not included.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002 ^[6]
Method	Repeated measurements model
Parameter estimate	Difference
Point estimate	-8.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.1
upper limit	-3.2

Notes:

[6] - The statistical test was not controlled for multiplicity.

Secondary: Amount of topical corticosteroid (TCS) used through Week 16 assuming all TCS used from the non-returned tubes

End point title	Amount of topical corticosteroid (TCS) used through Week 16 assuming all TCS used from the non-returned tubes
End point description: Assessed as the amount of TCS weighed from previous visits, assuming all TCS was used from the non-returned tubes. The analysis was based on the full analysis set. The results of Week 15 to Week 16 are reported below.	
End point type	Secondary
End point timeframe: Week 0 to Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: gram(s)				
arithmetic mean (standard error)	15.3 (± 2.26)	24.8 (± 3.27)		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description: Data collected after permanent discontinuation of investigational medicinal product or initiation of rescue medication were not included.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS

Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.017 ^[7]
Method	Repeated measurements model
Parameter estimate	Difference
Point estimate	-9.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.3
upper limit	-1.7

Notes:

[7] - The statistical test was not controlled for multiplicity.

Secondary: Number of atopic dermatitis flares through Week 16

End point title	Number of atopic dermatitis flares through Week 16
End point description:	
Assessed as appearance of new flares since the previous visit. The analysis was based on the full analysis set and the results reported are based on all observed data.	
End point type	Secondary
End point timeframe:	
Week 0 to Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: Number of flares	119	75		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of days without topical treatment use from baseline to Week 16

End point title	Number of days without topical treatment use from baseline to Week 16
End point description:	
Subjects assessed their use of topical treatment over the past 24 hours using a response scale ('yes', 'no'). Results were presented as weekly average. The analysis was based on the full analysis set and results of Week 16 are reported below.	
End point type	Secondary
End point timeframe:	
Week 0 to Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	210	96		
Units: days				
arithmetic mean (standard error)	3.4 ($\pm$ 0.19)	3.0 ($\pm$ 0.27)		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description:	
Data collected after permanent discontinuation of investigational medicinal product or initiation of rescue medication were not included.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	306
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.17 [8]
Method	Repeated measurements model
Parameter estimate	Difference
Point estimate	0.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2
upper limit	1.1

Notes:

[8] - The statistical test was not controlled for multiplicity.

Secondary: Subjects achieving at least 50% reduction in Eczema Area and Severity Index (EASI) at Week 16

End point title	Subjects achieving at least 50% reduction in Eczema Area and Severity Index (EASI) at Week 16
End point description:	
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition. The analysis was based on the full analysis set.	
End point type	Secondary
End point timeframe:	
At Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: Number of subjects	200	73		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description:	
Subjects meeting the endpoint were defined as responders. Subjects with missing data at Week 16 or who received rescue medication prior to Week 16 were defined as non-responders, independently of their EASI value at Week 16. The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[9]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	21.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.3
upper limit	31.3

Notes:

[9] - The statistical test was not controlled for multiplicity.

Secondary: Subjects achieving at least 90% reduction in Eczema Area and Severity Index (EASI) at Week 16

End point title	Subjects achieving at least 90% reduction in Eczema Area and Severity Index (EASI) at Week 16
End point description:	
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition. The analysis was based on the full analysis set.	
End point type	Secondary
End point timeframe:	
At Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: Number of subjects	83	27		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description:	
Subjects meeting the endpoint were defined as responders. Subjects with missing data at Week 16 or who received rescue medication prior to Week 16 were defined as non-responders, independently of their EASI value at Week 16. The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.022 ^[10]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	11.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.1
upper limit	20.7

Notes:

[10] - The statistical test was not controlled for multiplicity.

Secondary: Change from baseline to Week 16 in Eczema Area and Severity Index (EASI) score

End point title	Change from baseline to Week 16 in Eczema Area and Severity Index (EASI) score
End point description:	
EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition. The analysis was based on the full analysis set.	
End point type	Secondary
End point timeframe:	
Week 0 to Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	229	108		
Units: Units on a scale				
arithmetic mean (standard error)	-21.0 (± 0.67)	-15.6 (± 0.96)		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description:	
Data collected after permanent discontinuation of investigational medicinal product or initiation of rescue medication were not included.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	337
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[11]
Method	Repeated measurement model
Parameter estimate	Difference
Point estimate	-5.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.7
upper limit	-3.1

Notes:

[11] - The statistical test was not controlled for multiplicity.

Secondary: Subjects achieving at least 50% reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

End point title	Subjects achieving at least 50% reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16
End point description:	
SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition. The analysis was based on the full analysis set.	
End point type	Secondary
End point timeframe:	
At Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: Number of subjects	154	48		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description: Subjects meeting the endpoint were defined as responders. Subjects with missing data at Week 16 or who received rescue medication prior to Week 16 were defined as non-responders, independently of their SCORAD value at Week 16. The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[12]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	22.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	12.4
upper limit	33.3

Notes:

[12] - The statistical test was not controlled for multiplicity.

Secondary: Subjects achieving at least 75% reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

End point title	Subjects achieving at least 75% reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16
End point description: SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition The analysis was based on the full analysis set.	
End point type	Secondary
End point timeframe: At Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	252	126		
Units: Number of subjects	60	16		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description:	
Subjects meeting the endpoint were defined as responders. Subjects with missing data at Week 16 or who received rescue medication prior to Week 16 were defined as non-responders, independently of their SCORAD value at Week 16. The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	378
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.012 ^[13]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	11.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.2
upper limit	19

Notes:

[13] - The statistical test was not controlled for multiplicity.

Secondary: Change from baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (weekly average)

End point title	Change from baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (weekly average)
End point description:	
Worst Daily Pruritus NRS is used by the subject to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale. The analysis was based on the full analysis set.	
End point type	Secondary
End point timeframe:	
Week 0 to Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	221	100		
Units: Units on a scale				
arithmetic mean (standard error)	-4.1 (± 0.15)	-2.9 (± 0.21)		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description: Data collected after permanent discontinuation of investigational medicinal product or initiation of rescue medication were not included.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	321
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[14]
Method	Repeated measurements model
Parameter estimate	Difference
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	-0.7

Notes:

[14] - The statistical test was not controlled for multiplicity.

Secondary: Reduction from baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at least 4 points among participants with baseline DLQI ≥4

End point title	Reduction from baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at least 4 points among participants with baseline DLQI ≥4
End point description: DLQI is used by the subject to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL. The analysis was based on subjects in the full analysis set with DLQI of at least 4 at baseline (Week 0).	
End point type	Secondary
End point timeframe: Week 0 to Week 16	

End point values	Tralokinumab Q2W+TCS	Placebo+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	248	123		
Units: Number of subjects	207	81		

Statistical analyses

Statistical analysis title	Tralokinumab Q2W+TCS vs placebo+TCS
Statistical analysis description: Subjects meeting the endpoint were defined as responders. Subjects with missing data at Week 16 or who received rescue medication prior to Week 16 were defined as non-responders, independently of their DLQI value at Week 16. The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.	
Comparison groups	Tralokinumab Q2W+TCS v Placebo+TCS
Number of subjects included in analysis	371
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 ^[15]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	17.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	8
upper limit	27.1

Notes:

[15] - The statistical test was not controlled for multiplicity.

Secondary: Subjects with Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Week 32 among subjects with IGA score of 0 or 1 at Week 16 after initial randomisation to tralokinumab

End point title	Subjects with Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) at Week 32 among subjects with IGA score of 0 or 1 at Week 16 after initial randomisation to tralokinumab
End point description: IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe). The analysis was based on the subjects in the continuation treatment analysis set treated with tralokinumab Q2W+TCS in the initial treatment period and who achieved IGA score of 0 or 1 at Week 16 without rescue medication. Subjects with missing data at Week 16 or who received rescue medication prior to Week 32 were not included in the analysis.	
End point type	Secondary
End point timeframe: At Week 32	

End point values	Tralokinumab R/Q2W+TCS	Tralokinumab R/Q4W+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	48	49		
Units: Number of subjects	43	38		

Statistical analyses

No statistical analyses for this end point

Secondary: Subjects achieving at least 75% reduction in Eczema Area and Severity Index (EASI) at Week 32 among subjects who had achieved at least 75% reduction in EASI at Week 16 after initial randomisation to tralokinumab

End point title	Subjects achieving at least 75% reduction in Eczema Area and Severity Index (EASI) at Week 32 among subjects who had achieved at least 75% reduction in EASI at Week 16 after initial randomisation to tralokinumab
-----------------	---

End point description:

EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition. The analysis was based on subjects in the continuation treatment analysis set treated with tralokinumab Q2W+TCS in the initial treatment period and who achieved at least 75% reduction in EASI at Week 16 without rescue medication. Subjects with missing data at Week 16 or who received rescue medication prior to Week 32 were not included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 32

End point values	Tralokinumab R/Q2W+TCS	Tralokinumab R/Q4W+TCS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	67	65		
Units: Number of subjects	62	59		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All adverse events were collected from the time of signed informed consent form to the end of the trial (safety follow-up visit at Week 46).

Adverse event reporting additional description:

The analysis was conducted based on the safety analysis set which consisted of subjects exposed to at least 1 dose of investigational medicinal product.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20
--------------------	----

Reporting groups

Reporting group title	Initial treatment period - Tralokinumab Q2W+TCS
-----------------------	---

Reporting group description:

Subjects in the initial treatment period (Week 0 to Week 16) treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed. Subjects received a loading dose of 600 mg tralokinumab at Week 0 followed by a dose of 300 mg tralokinumab Q2W from Week 2 to Week 16.

Reporting group title	Initial treatment period - Placebo+TCS
-----------------------	--

Reporting group description:

Subjects in the initial treatment period (Week 0 to Week 16) treated with placebo every second week and topical corticosteroid (TCS) as needed. Subjects were administered placebo at Week 0 followed by administration of placebo every second week from Week 2 to Week 16.

Reporting group title	Continuation treatment period - Tralokinumab R/Q2W+TCS
-----------------------	--

Reporting group description:

Subjects treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as IGA score of 0 or 1 at Week 16 or a reduction in EASI of at least 75% achieved without rescue medication, and re-randomised to tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32). Subjects received a dose of 300 mg tralokinumab Q2W from Week 16 to Week 30.

Reporting group title	Continuation treatment period - Tralokinumab R/Q4W+TCS
-----------------------	--

Reporting group description:

Subjects treated with tralokinumab every second week and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as IGA score of 0 or 1 at Week 16 or a reduction in EASI of at least 75% at Week 16 achieved without rescue medication, and re-randomised to tralokinumab every fourth week (Q4W) and TCS as needed in the continuation treatment period (Week 16 to Week 32). Subjects received alternating doses of 300 mg tralokinumab and placebo Q2W from Week 16 to Week 30.

Reporting group title	Continuation treatment period - Tralokinumab NR/Q2W+TCS
-----------------------	---

Reporting group description:

Subjects treated with tralokinumab every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), without a clinical response at Week 16 (NR: non-responder) i.e. not having IGA score of 0 or 1 at Week 16 or a reduction in EASI of at least 75% at Week 16, and assigned tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32). Subjects received a dose of 300 mg tralokinumab Q2W from Week 16 to Week 30.

Reporting group title	Continuation treatment period -Placebo NR/tralokinumab Q2W+TCS
-----------------------	--

Reporting group description:

Subjects treated with placebo every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), without a clinical response at Week 16 (NR: non-responder) i.e. not having IGA score of 0 or 1 at Week 16 or a reduction in EASI of at least 75% at Week 16, and assigned tralokinumab Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32). Subject received a dose of 300 mg tralokinumab Q2W from Week 16 to Week 30.

Reporting group title	Continuation treatment period - Placebo R/placebo+TCS
-----------------------	---

Reporting group description:

Subjects treated with placebo every second week (Q2W) and topical corticosteroid (TCS) as needed in the initial treatment period (Week 0 to Week 16), with a clinical response at Week 16 (R: responder) defined as IGA score of 0 or 1 at Week 16 or a reduction in EASI of at least 75% at Week 16 achieved without rescue medication, and assigned placebo Q2W and TCS as needed in the continuation treatment period (Week 16 to Week 32). Subjects were administered placebo Q2W from Week 16 to Week 30.

Reporting group title	Safety follow-up period - All treatment groups
-----------------------	--

Reporting group description:

Subjects who spent any amount of time in the safety follow-up period, independently of the treatment(s) received before. No treatment was administered to the subjects during the safety follow-up period. In selected countries, eligible subjects who completed treatment could transfer to an open-label long-term extension trial (conducted under a separate protocol) at any any time during the safety follow-up period.

Serious adverse events	Initial treatment period - Tralokinumab Q2W+TCS	Initial treatment period - Placebo+TCS	Continuation treatment period - Tralokinumab R/Q2W+TCS
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 252 (0.79%)	4 / 126 (3.17%)	3 / 69 (4.35%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ligament rupture			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	1 / 69 (1.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Ischaemic stroke			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 252 (0.40%)	0 / 126 (0.00%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastroduodenitis			
subjects affected / exposed	1 / 252 (0.40%)	0 / 126 (0.00%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	0 / 252 (0.00%)	1 / 126 (0.79%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	1 / 69 (1.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis infected			

subjects affected / exposed	0 / 252 (0.00%)	1 / 126 (0.79%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	1 / 69 (1.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 252 (0.00%)	1 / 126 (0.79%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 252 (0.00%)	1 / 126 (0.79%)	0 / 69 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 252 (0.00%)	0 / 126 (0.00%)	1 / 69 (1.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Continuation treatment period - Tralokinumab R/Q4W+TCS	Continuation treatment period - Tralokinumab NR/Q2W+TCS	Continuation treatment period - Placebo NR/tralokinumab Q2W+TCS
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 69 (0.00%)	2 / 95 (2.11%)	0 / 79 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			

subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ligament rupture			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 69 (0.00%)	1 / 95 (1.05%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastroduodenitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			

subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 69 (0.00%)	1 / 95 (1.05%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis infected			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 69 (0.00%)	0 / 95 (0.00%)	0 / 79 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Continuation treatment period - Placebo R/placebo+TCS	Safety follow-up period - All treatment groups	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 41 (2.44%)	3 / 278 (1.08%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Invasive ductal breast carcinoma			
subjects affected / exposed	1 / 41 (2.44%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	0 / 41 (0.00%)	1 / 278 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ligament rupture			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 41 (0.00%)	1 / 278 (0.36%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Gastrointestinal disorders			
Gastroduodenitis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 41 (0.00%)	1 / 278 (0.36%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis infected			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis clostridial			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			

subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis aseptic			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 278 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Initial treatment period - Tralokinumab Q2W+TCS	Initial treatment period - Placebo+TCS	Continuation treatment period - Tralokinumab R/Q2W+TCS
Total subjects affected by non-serious adverse events			
subjects affected / exposed	118 / 252 (46.83%)	36 / 126 (28.57%)	30 / 69 (43.48%)
Nervous system disorders			
Headache			
subjects affected / exposed	22 / 252 (8.73%)	6 / 126 (4.76%)	2 / 69 (2.90%)
occurrences (all)	26	9	2
General disorders and administration site conditions			
Injection site reaction			
subjects affected / exposed	17 / 252 (6.75%)	0 / 126 (0.00%)	5 / 69 (7.25%)
occurrences (all)	30	0	14
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	8 / 252 (3.17%)	2 / 126 (1.59%)	4 / 69 (5.80%)
occurrences (all)	8	2	4
Nausea			
subjects affected / exposed	0 / 252 (0.00%)	1 / 126 (0.79%)	3 / 69 (4.35%)
occurrences (all)	0	1	3
Skin and subcutaneous tissue disorders			

Dermatitis atopic subjects affected / exposed occurrences (all)	6 / 252 (2.38%) 8	10 / 126 (7.94%) 12	1 / 69 (1.45%) 1
Infections and infestations			
Conjunctivitis subjects affected / exposed occurrences (all)	28 / 252 (11.11%) 32	4 / 126 (3.17%) 4	4 / 69 (5.80%) 4
Oral herpes subjects affected / exposed occurrences (all)	4 / 252 (1.59%) 6	1 / 126 (0.79%) 2	3 / 69 (4.35%) 3
Upper respiratory tract infection subjects affected / exposed occurrences (all)	19 / 252 (7.54%) 21	6 / 126 (4.76%) 7	7 / 69 (10.14%) 8
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	49 / 252 (19.44%) 64	14 / 126 (11.11%) 18	12 / 69 (17.39%) 13

Non-serious adverse events	Continuation treatment period - Tralokinumab R/Q4W+TCS	Continuation treatment period - Tralokinumab NR/Q2W+TCS	Continuation treatment period - Placebo NR/tralokinumab Q2W+TCS
Total subjects affected by non-serious adverse events subjects affected / exposed	24 / 69 (34.78%)	41 / 95 (43.16%)	32 / 79 (40.51%)
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	5 / 69 (7.25%) 5	7 / 95 (7.37%) 7	2 / 79 (2.53%) 2
General disorders and administration site conditions			
Injection site reaction subjects affected / exposed occurrences (all)	4 / 69 (5.80%) 9	5 / 95 (5.26%) 5	2 / 79 (2.53%) 2
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1	1 / 95 (1.05%) 2	2 / 79 (2.53%) 2
Nausea subjects affected / exposed occurrences (all)	4 / 69 (5.80%) 4	3 / 95 (3.16%) 4	1 / 79 (1.27%) 1
Skin and subcutaneous tissue disorders			

Dermatitis atopic subjects affected / exposed occurrences (all)	1 / 69 (1.45%) 1	8 / 95 (8.42%) 8	6 / 79 (7.59%) 7
Infections and infestations			
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 69 (0.00%) 0	3 / 95 (3.16%) 3	3 / 79 (3.80%) 3
Oral herpes subjects affected / exposed occurrences (all)	4 / 69 (5.80%) 4	4 / 95 (4.21%) 5	2 / 79 (2.53%) 2
Upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 69 (4.35%) 3	6 / 95 (6.32%) 7	3 / 79 (3.80%) 3
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	9 / 69 (13.04%) 10	20 / 95 (21.05%) 28	15 / 79 (18.99%) 15

Non-serious adverse events	Continuation treatment period - Placebo R/placebo+TCS	Safety follow-up period - All treatment groups	
Total subjects affected by non-serious adverse events subjects affected / exposed	12 / 41 (29.27%)	10 / 278 (3.60%)	
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	3 / 278 (1.08%) 3	
General disorders and administration site conditions			
Injection site reaction subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	0 / 278 (0.00%) 0	
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	1 / 278 (0.36%) 1	
Nausea subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	2 / 278 (0.72%) 2	
Skin and subcutaneous tissue disorders			

Dermatitis atopic subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	2 / 278 (0.72%) 2	
Infections and infestations Conjunctivitis subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 278 (0.00%) 0	
Oral herpes subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 278 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	2 / 278 (0.72%) 2	
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	7 / 41 (17.07%) 8	0 / 278 (0.00%) 0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 April 2018	The main reason for the amendment was a change in the procedure for safety monitoring of trial subjects after administration of the investigational medicinal product. This change was based on the evaluation of safety data from both completed and ongoing trials with tralokinumab in atopic dermatitis and asthma which warranted a shorter observation period.
29 August 2018	The main reason for the amendment was to introduce the possibility for eligible subjects in selected countries to participate to an open-label long-term extension trial (conducted under a separate protocol) without completing the safety follow-up period in the present trial. This was due to the availability of a new anti-drug antibodies (ADA) assay with improved tralokinumab tolerance making it possible to detect the presence or absence of ADA in the presence of tralokinumab. This was not possible with the previous assay and ADA sampling at the end of the 14-week off-treatment safety follow-up period was therefore originally required for ADA evaluation. Thus, in selected countries, the new ADA assay allowed eligible subjects who had completed treatment in the present trial to continue into the long-term extension trial without completing the safety follow-up period in the present trial. These subjects had their safety follow-up period after end of treatment in the long-term extension trial.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported